Kronox Lab Sciences share price today

Kronox Lab Sciences Ltd's share price was ₹197.29 at the close on 4 November 2026. It has been rising for 18 weeks. That is 20.8% above its average price over the last 200 trading days. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 15 weeks in a row.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Kronox Lab Sciences Ltd is in stage 2. The phase helps read everything below.

Since its first close in our records, on 15 May 2026, it has traded between ₹132 and ₹217, and at that close it sat 77% of the way up from that low.

Over the last 6 months the share price moved +50% while the NIFTY 500 moved −3%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

9 points in one quarter, profit up on a year earlier for 8 quarters in a row and indian funds and insurers (DIIs) raised their stake for 5 quarters in a row.

1. Promoters cut their stake by 9.9 points in one quarter

   From 74.2% to 64.3% in the September 2026 quarter.

2. Profit up on a year earlier for 8 quarters in a row

   In the June 2026 quarter profit was ₹7 crore, +16.2% on a year earlier.

3. Indian funds and insurers (DIIs) raised their stake for 5 quarters in a row

   From 1.7% to 2.5% of the company by the September 2026 quarter.

For April to June 2026 (the quarter ended 30 June 2026), Kronox Lab Sciences reported revenue of ₹28.4 crore, up 16.9% from ₹24.3 crore a year earlier, and a profit of ₹7.30 crore, up 16.2% from ₹6.28 crore.

Kronox Lab Sciences results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Kronox Lab Sciences closed at ₹197.29 on 4 November 2026. Its highest weekly close since May 2026 was ₹216.90 on 28 September 2026.

Kronox Lab Sciences share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

28 weekly closes from 15 May 2026 to 4 November 2026.

4 Nov 2026: Kronox Lab Sciences closed at ₹197.29, up 5.9% on the week and down 4.1% on the month. Our read, 10 Oct 2026: Cash-backed earnings provide a foundation, but treasury income and delayed expansion limit the case for an operating acceleration.

Earlier

• 9 Sep 2026: ex-date for a dividend of ₹0.50 a share.
• Results for April to June 2026: Revenue up 16.9% and profit up 16.2% on a year earlier.

Our read of the business

Bronze evidence depth supports a cautious forward view.

April to June 2026: Sales growth improved, but operating margin diluted.

Our read after the April to June 2026 results, written 10 October 2026.

Kronox Lab Sciences paid ₹0.50 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.25% at the ₹197.29 close on 4 November 2026. The last was a dividend of ₹0.50 a share, ex-date 9 September 2026.

Kronox Lab Sciences dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here.

Yes. Kronox Lab Sciences Ltd paid out 7% of its profit as dividends in FY26, and it paid a dividend in 3 of its last 7 reported years.

From the NSE corporate-actions record, read 5 November 2026.

Kronox Lab Sciences' management made 0 promises we could check against what it later reported.

Our read after the April to June 2026 results, written 10 October 2026.

What is changing at Kronox Lab Sciences, from the latest results and calls: sales recovery, cash-funded operating base and qualified product offering.

• Sales recovery. Latest sales growth offers a demand signal, but margin dilution limits the profit benefit. ✓ fact
• Cash-funded operating base. Aggregate cash conversion gives the business room to finance growth internally. ⚠ estimate
• Qualified product offering. The company manufactures high-purity chemicals to specified industry standards. ✓ fact
• Conditional Dahej expansion. Dahej can add a growth route once construction and customer demand are demonstrated. ⚠ estimate

We check 16 kinds of change in every company, such as costs spread over more sales, higher-value products, new orders, new regions or falling debt, against its reported numbers and what management said on its calls. Only changes the numbers back are shown.

Our read after the April to June 2026 results, written 10 October 2026.

A subsequent result showing falling sales and operating profit together, with continued inventory accumulation, would break the case that the latest sales improvement can sustain cash-backed earnings.

Each change stops working if

• Sales recovery: Sales growth reverses and operating profit falls in the next reported quarter.
• Cash-funded operating base: Operating cash conversion deteriorates while expansion expenditure increases.
• Qualified product offering: Product compliance failures interrupt sales or customers require price concessions that reduce operating profit.

The main risks

• : Interest income makes reported profit growth look faster than operating growth. ⚠ estimate
• : Delayed Dahej construction pushes out the expansion contribution. ✓ fact
• : Latest margin dilution weakens the operating-leverage interpretation. ⚠ estimate
• : Inventory and receivables absorbed more cash in the latest year. ⚠ estimate

Our read after the April to June 2026 results, written 10 October 2026.

When Kronox Lab Sciences reports July to September 2026, these are the 5 checks that show whether the story is still on course. First: Reported profit increases while operating profit stagnates or declines.

Kronox Lab Sciences is on one of our India lists: Momentum stocks.

Kronox Lab Sciences Ltd earned ₹7.3 Cr of net profit in the Jun 2026 quarter, +16.2% on the same quarter a year earlier. That is the 8th quarter in a row of profit growth. Full-year FY26 profit was ₹28.0 Cr. Over 6 years profit has grown 20.8% a year on average. That is 25.7% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹6.3 Cr.

For the full year, FY26 profit was ₹28.0 Cr (+12.0% on the year before).

Why profit moved: revenue changed +16.9% on a year earlier and the margin moved −1.1 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed +11.7% and revenue +6.2%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

Kronox Lab Sciences Ltd reported ₹28.4 Cr of revenue in the Jun 2026 quarter, +16.9% on the same quarter a year earlier. Over 6 years it has grown 12.4% a year on average. The last full year, FY26, came in at ₹101 Cr. The last four reported quarters add to ₹105 Cr.

Revenue is everything the company billed its customers in the period.

FY26 revenue was ₹101 Cr, +1.0% on the year before.

Recent pace: the last four quarters grew +6.2% on average, against 12.4% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +6.1%, against +8.7% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +11.6%, against +16.3% a year (rolling over).

Kronox Lab Sciences Ltd's operating margin was 31.7% in the Jun 2026 quarter, 1.1 percentage points lower than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 7 years it has been between 23.0% and 34.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why this happened. June revenue increased 16.9% and operating profit increased 12.8%. The business retained additional operating profit, but margin declined because operating profit grew more slowly than sales. Volume, price and mix contributions are unknown; competitor response and customer benefit retention cannot be established. The benefit already delivered is visible in the result, while persistence remains a forecast.

Why the margin moved: operating margin changed −1.1 percentage points on the year while gross margin changed −0.9 points. So the drop came mostly from the gross margin, which means input costs and prices charged.

When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold.

Over the last 3 years, 97% of Kronox Lab Sciences Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹24.0 Cr of operating cash against ₹28.0 Cr of profit. After ₹3.0 Cr of spending on assets, ₹21.0 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Why this happened. The Self-Funded Growth Engine applies to the historical cash record: aggregate operating cash flow broadly tracks profit and estimated free cash flow remains positive. This establishes past funding capacity, not the economics of a future plant. Construction expenditure and working-capital needs could reduce the cash available to shareholders.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 97% of profit came in as cash: the cash cycle got 11 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives.

What to look at next: the bigger use of cash is spending on new assets, at 4.5× depreciation over three years. The next section checks what that spending is building.

Kronox Lab Sciences Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 90 days in FY26, up from 79 days in FY21. It spent ₹18.0 Cr on assets over the last 3 years. Customers take 76 days to pay, and stock sits for 66 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Why this happened. The annual report acknowledges that work had not started and goals production in two years and full operation in three years. The Capex Inflection Point therefore does not support a near-term contribution. Construction, qualification, utilization and incremental cash returns remain separate hurdles. No Dahej earnings contribution is included as delivered performance, and the relative schedule does not establish a verified commissioning date.

At FY26 sales of ₹101 Cr, each day of that cycle ties up about ₹0.3 Cr, so roughly ₹25.0 Cr is tied up in the business at any time.

FY26: customers took 76 days to pay and stock sat for 66 days, about 2.2 months of sales sitting as stock, for a full cycle of 90 days, longer than FY21's 79.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 66 days. Customers pay about 76 days after that. Suppliers are paid at 52 days. Together that makes the 90-day cycle.

Spending on assets: ₹18.0 Cr over the last 3 years, against ₹4.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹1.0 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Kronox Lab Sciences Ltd's P/E is 25.7×, in the middle of its own history: higher than 65% of past readings. Its usual P/E (the middle reading) is 23.3×, over 2.4 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple.

Worked out from its price on 11 October 2026, Kronox Lab Sciences Ltd's share price assumed profit growth of about 14.8% a year. Over the past 6 years its profit actually grew 20.8% a year. Today its P/E is 25.7×, higher than 65% of its own last 2.4 years.

This works the share price backwards. It asks one question: what yearly profit growth does the price already assume? The answer is the growth rate at which eleven years of profit (six years of growth, then five years of slowing) add up to that day's market value, after each year is discounted at 11%.

This is a one-day reading, taken on 11 October 2026. Every other number on this page, the multiple included, uses the latest price as of 4 November 2026. A higher price assumes more growth and a lower price less, so it changes whenever the price changes, and this page does not update it between measurements.

Kronox Lab Sciences Ltd's business is giving mixed signals. There is no clear direction across the growth lines, with ROCE steady at 37.2%; each line tells part of the story. This is based on 11 quarters of 3 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: when the lines disagree, each line above matters more than any single label.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Kronox Lab Sciences Ltd's story is not scored yet against the checks our research set on 10 October 2026. Where it sits in its own cycle: TROUGH. Still open: A subsequent result showing falling sales and operating profit together, with continued inventory accumulation, would break the case that the latest sales improvement can sustain cash-backed earnings.

NOT YET CHECKED

Our read, 10 October 2026. Cash-backed earnings provide a foundation, but treasury income and delayed expansion limit the case for an operating acceleration.

From the numbers. The supplied operating engine places the business near a trough, with earnings recovering; the separate price curve is in stage 2. The operating classification is tentative because June margin declined and the…

From the price. Price stage 2, week 18, above its 200-day line, relative strength rising.

From the research. Cash-backed earnings provide a foundation, but treasury income and delayed expansion limit the case for an operating acceleration.

Where they disagree. The supplied operating engine places the business near a trough, with earnings recovering; the separate price curve is in stage 2.

What is proven. Cash-backed earnings provide a foundation, but treasury income and delayed expansion limit the case for an operating acceleration.

What is not proven yet. A subsequent result showing falling sales and operating profit together, with continued inventory accumulation, would break the case that the latest sales improvement can sustain cash-backed earnings.

What would change our mind. A subsequent result showing falling sales and operating profit together, with continued inventory accumulation, would break the case that the latest sales improvement can sustain cash-backed earnings.

The test written in advance. A subsequent result showing falling sales and operating profit together, with continued inventory accumulation, would break the case that the latest sales improvement can sustain cash-backed earnings. Measured by: the thesis as written as stated by the next result.

The key numbers to watch, and the level that would change the picture

Everything further down this page is evidence for or against these.

What the surface reading misses. The surface reading is: Higher sales and profit suggest an acceleration. The research reads it further: Operating profit grew more slowly than revenue, so the result demonstrates additional sales without operating-leverage confirmation.

What the surface reading misses. The surface reading is: Profit growth appears to signal rapid business expansion. The research reads it further: Sales were unchanged; improved operating margin, rather than revenue expansion, explains the observable operating improvement.

Sources: our stock research file (10 October 2026) · quarterly results through Jun 2026. The story check is re-scored every results season; the record below never changes.

The whole page in one table. Each row links to its section.

Kronox Lab Sciences Ltd earned a ROCE of 36% in FY26. Its return on capital used (ROIC) is 23.7 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 27.7% net margin and 0.79× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY26): a 27.7% net margin × 0.79× asset turnover × 1.10× leverage (assets divided by equity) ≈ 24.1% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed.

The key test, return on capital used minus the cost of capital: 35.7% − 12.0% = +23.7 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value.

The 35.7% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 39.7%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.

Kronox Lab Sciences Ltd had ₹2.0 Cr of borrowings against ₹116 Cr of equity in FY26, so its debt is 0.02× its equity. Over 5 years borrowings went from ₹4.0 Cr to ₹2.0 Cr. Over the last 3 of those years it spent ₹18.0 Cr on assets.

Debt-to-equity shows how much of the business is paid for with borrowed money. Interest cover shows how many times operating profit pays the interest bill. Low debt and high cover are the safe combination.

The spending on assets is being paid for from cash, not new debt.

Promoters cut their stake in Kronox Lab Sciences Ltd by 9.9 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 64.3% of the company. Foreign institutions moved −0.5 points over the same period, to 0.1%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Over the last two years: Promoters: −9.9 points over 8 quarters, to 64.3%; Foreign institutions: −0.5 points over 8 quarters, to 0.1%; Domestic institutions: +0.0 points over 8 quarters, to 2.5%.

Why the owners changed: promoters drove it (−9.9 points), together with foreign institutions (−0.5 points). They reduced their stake.

For Kronox Lab Sciences Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

51.6 out of 100, rank 16 of 30 in Speciality Chemicals, with 74% of the evidence available.

Kronox Lab Sciences Ltd scores 51.6 out of 100 against the 30 companies it is compared with in Speciality Chemicals, ranking 16. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.

The four parts add up to the total exactly: 10.4 + 21.2 + 8.2 + 11.8 = 51.6. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Kronox Lab Sciences ranks 16 of 30 Speciality Chemicals companies on the 4-Factor Sector Score, with 51.6 out of 100.

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Speciality Chemicals, all 30 compared on one page.

Kronox Lab Sciences is the 24th largest of 30 Speciality Chemicals companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Vikram Thermo (India), Sunshield Chemicals and Amines & Plasticizers. Just below it: Transpek Industry, Chemcon Speciality Chemicals and Amal.

Speciality Chemicals companies close in size

21. Vikram Thermo (India) Ltd ₹1,129 crore
22. Sunshield Chemicals Ltd ₹882 crore
23. Amines & Plasticizers Ltd ₹782 crore
24. Kronox Lab Sciences Ltd ₹691 crore
25. Transpek Industry Ltd ₹682 crore
26. Chemcon Speciality Chemicals Ltd ₹666 crore
27. Amal Ltd ₹658 crore

All 30 Speciality Chemicals companies, largest first

Companies close in size in other industries

1820. Automotive Stampings & Assemblies Ltd ₹695 crore · Auto Ancillaries - Spare Parts Accessories
1821. SRIT India Ltd ₹692 crore
1822. Kronox Lab Sciences Ltd ₹691 crore
1823. RBZ Jewellers Ltd ₹690 crore · Diamond, Gems & Jewellery
1824. Vascon Engineers Ltd ₹690 crore · Construction & Contracting

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.